11/2/2026

speaker
Conference Call Operator
Operator

Good afternoon and welcome to the Travere Therapeutics third quarter 2026 financial results conference call. Today's call is being recorded. At this time, I would like to turn the conference call over to Ryan Hayes, investor relations analyst. Please go ahead, Ryan.

speaker
Ryan Hayes
Investor Relations Analyst

Thank you, operator. Good afternoon and welcome to Travere Therapeutics' third quarter 2026 financial results and corporate update call. Thank you all for joining. Today's call will be led by Dr. Eric Dube, our President and Chief Executive Officer. Eric will be joined in the prepared remarks by Peter Heerma, our Chief Commercial Officer, Dr. Jula Inrig, our Head of R&D and Chief Medical Officer, and Chris Cline, our Chief Financial Officer. Dr. Bill Rote, our Chief Research Officer, will join us for the Q&A. Before we begin, I would like to remind everyone that statements made during this call regarding matters that are not historical facts are forward looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties, and assumptions that may cause actual results, performance, and achievements to differ materially from those expressed or implied by the statement. Please see the forward-looking statement disclaimer on the company's press release issued earlier today, as well as the risk factors section in our forms 10-Q and 10-K filed with the SEC. In addition, any forward-looking statements represent our views only as of the date such statements are made, November 2nd, 2026. and Travere specifically disclaims any obligation to update such statements to reflect future information, events or circumstances. With that, let me now turn the call over to Eric.

speaker
Eric Dube
President and Chief Executive Officer

Good afternoon and thank you for joining us today as we discuss another quarter of excellent execution and continued momentum across Travere's commercial business and pipeline. Before turning to our results, I'd like to briefly reflect on my upcoming transition that was announced during the quarter. As I prepare to step down in December, I've been reflecting on the people and purpose that have shaped my time at Travere. Being part of this company has been the greatest privilege of my career, and I am deeply proud of what we've accomplished. I have never been more confident that Travere's best days are ahead. With an exceptional executive team, Life Changing Therapies and a Growing Pipeline, and an organization committed to delivering for patients. I've been in regular communication with Bradley as we plan for him joining Travere on December 1st. This time together has only strengthened my conviction that he is the perfect fit to lead Travere into its next chapter. He shares our commitment to patients and brings the experience, perspective, and leadership to build on our momentum. We are approaching this transition from a position of strength, and you'll hear that reflected in the progress we're sharing today. With that, let's turn to the advancements we've made for the quarter. The third quarter was marked by excellent execution across our business and continued progress against our four key pillars of our strategy to drive both near and long-term growth. As we enter the final months of the year and look ahead to 2027, I am very pleased with the momentum we have built and the increasingly durable growth profile of our company. At the center of this momentum is PhilSparry, where strong patient demand, growing conversion and consistent commercial execution supported significant revenue growth across iJ Nephropathy and FSGS. Quarterly net product sales surpassed $200 million for the first time, marking an important milestone as we continue to reach more patients. In IG nephropathy, Filspari continues to demonstrate its foundational role with strong demand, steady conversion to paid prescriptions, and consistently high patient adherence despite new market entrants. Importantly, we are not simply adding new patients each quarter. We are building on a growing base of patients who remain on therapy over time. This dynamic is a powerful driver of recurring revenue and reinforces our confidence in PhilSparry's long-term growth potential. In FSGS, we remain encouraged by the early launch performance with high adoption trends consistent with our expectations. We're still at the beginning of this opportunity and see substantial potential to reach more eligible patients as nephrologists gain experience with PhilSparry and Peter will provide additional details shortly. This continued commercial momentum reinforces our confidence in achieving or exceeding more than $3 billion in annual PhilSparry sales by 2033. We've also made important progress strengthening PhilSparry's U.S. patent portfolio, including a recently issued patent directed at certain methods of use in IG nephropathy and a notice of allowance for a patent application directed to certain methods of use in FSGS. The IGAD Patent and upon issuance, the FSGS Patent carry terms extending into 2037. Taking together this commercial momentum and progress in our patent portfolio reinforce our belief in PhilSparry's potential to reach more patients and continue growing beyond 2033. An important part of that long-term opportunity is reaching more patients earlier in their disease journey. We are also encouraged that earlier diagnosis and treatment of IgA nephropathy and FSGS are being recognized within the federal government through the recently published landmark HHS Kidney Care National Plan. For these rare kidney diseases, timely diagnosis can help physicians and patients consider appropriate treatment options earlier in the patient journey, reflecting more proactive kidney care. These developments reinforce our broader ambition to build a leading rare disease company with multiple opportunities for the long term. Beyond PhilSparry, we are making tangible progress advancing the next growth opportunities for Travere. With the potential to become the first disease modifying therapy for classical HCU, PEG-2-Batinase represents an important opportunity to improve the lives of the estimated 7,000 to 10,000 people in the U.S. living with this devastating disease. Jula will share more on the progress of this important program shortly. We're also advancing our newest pipeline asset, Sivor Brutinib. During the quarter, our licensing and collaboration agreement with Everest became effective, and our teams are making progress. Its potential differentiated profile and opportunity across multiple immune-mediated kidney diseases representing more than 130,000 prevalent patients adds another compelling dimension to our long-term growth strategy. As I look at Truvere today, I see a company with a proven ability to execute a growing and increasingly durable commercial franchise and a pipeline with multiple opportunities to deliver meaningful innovation. We have built the capabilities, relationships, and expertise to lead in rare kidney disease, and we are only beginning to realize the opportunity ahead. With that, I'll turn the call over to Peter for an update on our commercial performance.

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API

Investor presentation